301 related articles for article (PubMed ID: 33905554)
1. Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Hishida S; Kawakami K; Fujita Y; Kato T; Takai M; Iinuma K; Nakane K; Tsuchiya T; Koie T; Miura Y; Ito M; Mizutani K
Prostate; 2021 Jun; 81(9):592-602. PubMed ID: 33905554
[TBL] [Abstract][Full Text] [Related]
2. TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Sekino Y; Han X; Kawaguchi T; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Yasui W; Matsubara A
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412591
[TBL] [Abstract][Full Text] [Related]
3. Analysis of cabazitaxel-resistant mechanism in human castration-resistant prostate cancer.
Hongo H; Kosaka T; Oya M
Cancer Sci; 2018 Sep; 109(9):2937-2945. PubMed ID: 29989268
[TBL] [Abstract][Full Text] [Related]
4. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
Hongo H; Kosaka T; Suzuki Y; Mikami S; Fukada J; Oya M
Sci Rep; 2021 Nov; 11(1):22284. PubMed ID: 34782700
[TBL] [Abstract][Full Text] [Related]
6. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic potential of serum extracellular vesicles expressing prostate-specific membrane antigen in urologic malignancies.
Kawakami K; Fujita Y; Kato T; Horie K; Koie T; Umezawa K; Tsumoto H; Miura Y; Katagiri Y; Miyazaki T; Ohsawa I; Mizutani K; Ito M
Sci Rep; 2021 Jul; 11(1):15000. PubMed ID: 34294841
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening.
Hongo H; Kosaka T; Suzuki Y; Oya M
Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):59-66. PubMed ID: 34593983
[TBL] [Abstract][Full Text] [Related]
9. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
[TBL] [Abstract][Full Text] [Related]
10. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
11. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
12. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
[TBL] [Abstract][Full Text] [Related]
13. SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition.
Aguilar-Valdés A; Noriega LG; Tovar AR; Ibarra-Sánchez MJ; Sosa-Hernández VA; Maravillas-Montero JL; Martínez-Aguilar J
Biochem Biophys Res Commun; 2021 May; 552():23-29. PubMed ID: 33740661
[TBL] [Abstract][Full Text] [Related]
14. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways.
Lu X; Yang F; Chen D; Zhao Q; Chen D; Ping H; Xing N
Int J Biol Sci; 2020; 16(7):1121-1134. PubMed ID: 32174789
[TBL] [Abstract][Full Text] [Related]
15. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Dirican A; Atmaca H; Bozkurt E; Erten C; Karaca B; Uslu R
Clin Transl Oncol; 2015 Feb; 17(2):145-51. PubMed ID: 25060568
[TBL] [Abstract][Full Text] [Related]
16. Insulin Mediated Activation of PI3K/Akt Signalling Pathway Modifies the Proteomic Cargo of Extracellular Vesicles.
Liem M; Ang CS; Mathivanan S
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28842968
[TBL] [Abstract][Full Text] [Related]
17. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
[TBL] [Abstract][Full Text] [Related]
18. Sensitization to docetaxel in prostate cancer cells by green tea and quercetin.
Wang P; Henning SM; Heber D; Vadgama JV
J Nutr Biochem; 2015 Apr; 26(4):408-15. PubMed ID: 25655047
[TBL] [Abstract][Full Text] [Related]
19. INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
Chen H; Li H; Chen Q
Biochem Biophys Res Commun; 2016 Aug; 477(3):467-72. PubMed ID: 27318090
[TBL] [Abstract][Full Text] [Related]
20.
Kato T; Kawakami K; Mizutani K; Ando T; Sakai Y; Sakurai K; Toyota S; Ehara H; Ito H; Ito M
Cancer Genomics Proteomics; 2023; 20(5):456-468. PubMed ID: 37643783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]